文献速递糖尿病

GLP-1受体激动剂心血管效应在不同年龄组间的更新荟萃分析

Cardiovascular Effects of GLP‐1 Receptor Agonists Across Age Groups: An Updated Meta‐Analysis of Randomized Controlled Trials
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-28

结果显示,GLP-1RA在<65岁和≥65岁人群中均降低MACE风险,汇总HR分别为0.81和0.84。未发现明确的证据表明相对心血管效应随年龄不同而改变。

要点

  • GLP-1RA在<65岁及≥65岁人群中均显著降低MACE风险。
  • ≥65岁与<65岁人群的相对效应无明确差异(RHR 1.03)。
  • ≥75岁年龄组数据较少,结果解读需谨慎。

核心结论

  • GLP-1RA在所纳入试验人群中均降低MACE风险,未发现相对心血管效应因年龄不同而存在明确差异。

研究设计与样本

  • 系统检索PubMed和Embase至2026年7月1日,纳入在2型糖尿病或超重/肥胖成人中比较GLP-1RA与安慰剂的随机对照试验。
  • 采用随机效应模型合并<65岁和≥65岁人群的HR,并通过汇总≥65岁对<65岁的试验特异性HR比值(RHR)评估效应修饰。

主要发现

  • GLP-1RA在<65岁人群中降低MACE风险,汇总HR为0.81(95% CI 0.69–0.94;I²=64.1%)。
  • GLP-1RA在≥65岁人群中降低MACE风险,汇总HR为0.84(95% CI 0.79–0.90;I²=0.0%)。
  • ≥65岁对<65岁的汇总RHR为1.03(95% CI 0.85–1.25),未显示明确的效应修饰,但试验间异质性较高(I²=59.3%)。
  • 在报告三个年龄层(<65岁、65至<75岁、≥75岁)的试验中,均未发现明确的效应修饰证据,但仅4项试验提供数据,且≥75岁组人数相对较少。

关键数值与推荐

  • MACE定义为心血管死亡、非致死性心肌梗死和非致死性卒中的复合终点。
  • <65岁组汇总HR为0.81(95% CI 0.69–0.94;I²=64.1%)。
  • ≥65岁组汇总HR为0.84(95% CI 0.79–0.90;I²=0.0%)。
  • ≥65岁对<65岁的汇总RHR为1.03(95% CI 0.85–1.25)。
  • ≥75岁对<65岁的效应修饰评估仅基于4项试验的数据,且该年龄组样本相对较小。

临床怎么用

  • GLP-1RA的心血管获益在年轻和年长成人中均存在,年龄本身不应成为限制其用于心血管风险管理的单一因素。
  • ≥75岁人群的数据有限,在该年龄组中应用时仍需结合个体情况综合判断。

局限性

  • ≥75岁年龄组人数相对较少,且仅4项试验报告了三个年龄分层的数据。
  • ≥65岁对<65岁的RHR汇总存在较高的试验间异质性(I²=59.3%)。
  • 分析基于试验水平的汇总数据,未进行个体参与者数据的荟萃分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims To evaluate whether cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) differ by age. Materials and Methods PubMed and Embase were searched to 1 July 2026 for randomized placebo-controlled GLP-1RA trials in adults with type 2 diabetes or overweight/obesity reporting age-stratified major adverse cardiovascular events (MACE; a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke). Hazard ratios (HRs) for participants aged < 65 and ≥ 65 years were pooled using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp adjustment. Effect modification was assessed by pooling trial-specific ratios of HRs (RHRs) for ≥ 65 versus < 65 years. Where reported, effects were assessed across < 65, 65 to < 75 and ≥ 75 years. Results Eight trials (SUSTAIN-6, EXSCEL, Harmony Outcomes, PIONEER 6, REWIND, AMPLITUDE-O, SELECT and SOUL) comprising 71 926 participants were included. GLP-1RAs reduced MACE at < 65 years and ≥ 65 years, with pooled HRs of 0.81 (95% CI 0.69–0.94; I 2 = 64.1%) and 0.84 (95% CI 0.79–0.90; I 2 = 0.0%), respectively. The pooled RHR showed no clear evidence of effect modification (1.03, 95% CI 0.85–1.25), although between-trial heterogeneity was high (I 2 = 59.3%). Among trials reporting three age strata, RHRs showed no clear evidence of effect modification for 65 to < 75 or ≥ 75 years versus < 65 years, but data were available from only four trials, and the ≥ 75-year group was relatively small. Conclusions Across the included trial populations, GLP-1RAs lowered MACE in the age groups examined, with no clear evidence that relative cardiovascular effects differed by age.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Cardiovascular Effects of GLP‐1 Receptor Agonists Across Age Groups: An Updated Meta‐Analysis of Randomized Controlled Trials

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。